Logo image of NAVB

NAVIDEA BIOPHARMACEUTICALS I (NAVB) Stock Fundamental Analysis

NYSEARCA:NAVB - NYSE Arca - US63937X2027 - Common Stock - Currency: USD

0.0779  0 (-2.99%)

Fundamental Rating

0

NAVB gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. NAVB may be in some trouble as it scores bad on both profitability and health. NAVB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NAVB has reported negative net income.
NAVB had a negative operating cash flow in the past year.
In the past 5 years NAVB always reported negative net income.
In the past 5 years NAVB reported 4 times negative operating cash flow.
NAVB Yearly Net Income VS EBIT VS OCF VS FCFNAVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M

1.2 Ratios

Looking at the Return On Assets, with a value of -209.43%, NAVB is doing worse than 93.23% of the companies in the same industry.
Industry RankSector Rank
ROA -209.43%
ROE N/A
ROIC N/A
ROA(3y)-239.03%
ROA(5y)-242.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NAVB Yearly ROA, ROE, ROICNAVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 2K 4K 6K 8K 10K

1.3 Margins

NAVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAVB Yearly Profit, Operating, Gross MarginsNAVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K

More info and screens

0

2. Health

2.1 Basic Checks

NAVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NAVB has been increased compared to 1 year ago.
The debt/assets ratio for NAVB is higher compared to a year ago.
NAVB Yearly Shares OutstandingNAVB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
NAVB Yearly Total Debt VS Total AssetsNAVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

NAVB has an Altman-Z score of -70.66. This is a bad value and indicates that NAVB is not financially healthy and even has some risk of bankruptcy.
NAVB's Altman-Z score of -70.66 is on the low side compared to the rest of the industry. NAVB is outperformed by 98.18% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -70.66
ROIC/WACCN/A
WACC9.82%
NAVB Yearly LT Debt VS Equity VS FCFNAVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

NAVB has a Current Ratio of 0.84. This is a bad value and indicates that NAVB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of NAVB (0.84) is worse than 92.90% of its industry peers.
A Quick Ratio of 0.79 indicates that NAVB may have some problems paying its short term obligations.
NAVB has a Quick ratio of 0.79. This is amonst the worse of the industry: NAVB underperforms 93.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.79
NAVB Yearly Current Assets VS Current LiabilitesNAVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for NAVB have decreased strongly by -39.35% in the last year.
Looking at the last year, NAVB shows a very negative growth in Revenue. The Revenue has decreased by -87.65% in the last year.
Measured over the past years, NAVB shows a very negative growth in Revenue. The Revenue has been decreasing by -48.49% on average per year.
EPS 1Y (TTM)-39.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.1%
Revenue 1Y (TTM)-87.65%
Revenue growth 3Y-53.62%
Revenue growth 5Y-48.49%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NAVB Yearly Revenue VS EstimatesNAVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
NAVB Yearly EPS VS EstimatesNAVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2019 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NAVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NAVB Price Earnings VS Forward Price EarningsNAVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NAVB Per share dataNAVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NAVB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NAVIDEA BIOPHARMACEUTICALS I

NYSEARCA:NAVB (10/5/2023, 8:04:00 PM)

0.0779

0 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2023-08-11/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.76%
Ins Owner Change0%
Market Cap7.80M
Analysts82.86
Price Target5.1 (6446.85%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 118.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -209.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.03%
ROA(5y)-242.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 241.56%
Cap/Sales 389.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.79
Altman-Z -70.66
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)474.48%
Cap/Depr(5y)298.68%
Cap/Sales(3y)233.93%
Cap/Sales(5y)142.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%221.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.65%
Revenue growth 3Y-53.62%
Revenue growth 5Y-48.49%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.6%
OCF growth 3YN/A
OCF growth 5YN/A